(0) Modra Pharmaceuticals ( Modra ) today announced the appointment of Hemanshu Shah, Ph.D., MBA and Klaus Schollmeier, Ph.D. to its supervisory board. The new members bring more than 50 years of combined experience in the pharmaceutical and biotechnology industry, and will provide guidance critical for the acceleration of Modra s growth and business development efforts, as well as the company s plans for the advancement of lead clinical candidate, ModraDoc006/r, a boosted oral formulation of docetaxel. Modra recently presented preliminary data from its Phase IIb trial of ModraDoc006/r, which showed a positive safety and tolerability profile in metastatic castrate resistant prostate cancer.